Jan 05, 2021 / 01:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone, and thank you for joining us for our CEO conference. We're really to pleased have the CEO of Moderna, Stéphane Bancel, with us here this morning.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPAnd with that, Stéphane, maybe a first question here about the journey that the company and yourself have gone through. But last year, we saw true validation of the mRNA technology platform as the COVID-19 vaccine 1273 was both created and became your first commercial asset. Could you discuss what the journey has been like for you, as CEO, and what the last year has meant for the company?
Stephane Bancel - Moderna, Inc. - CEO & Director
Well, good morning, everybody, and thank you, Salveen, for having me. Happy new year, everybody.
So we started the company almost 10 years ago now with the idea of using messenger RNA to make protein inside the [body]. At the
Trustpilot
